BGLCBasic Materials · Specialty Chemicals

BGLC Stock Forecast: BioNexus Gene Lab Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$1.61

+8.78% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap

$4.7M

Ticker Nerd rank

24 / 100

Median analyst target

—

Analysts covering

—

Revenue$76K−96.6% y/y

Operating income−$312K

Net income−$286K

Free cash flow−$423K

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+9.5%

+5.9%

YTD

−59.2%

−62.6%

From 52W high

−73.2%

From 52W low

+22.0%

$1.32

$6.00

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

BGLC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioNexus Gene Lab Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Quality

Growth

Volatility

Issuance

Value

Revisions

Momentum

Size (96): Smaller than most of the companies we track.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BGLC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BGLC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BGLC appears on the weeks it earns a place.

Performance

BGLC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, BioNexus Gene Lab Corp. returned −62.6% against +17.5% for the S&P 500, dividends included.

BGLC vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BGLC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

BioNexus Gene Lab Corp. (BGLC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −1.0×
Price / sales: 1.5×
Price / book: 0.5×
EV / EBITDA: −0.6×

Growth & margins

Revenue growth (YoY): −96.6%
Earnings growth (YoY): −96.6%
Gross margin: 17.0%
Operating margin: −398.7%
Net margin: −82.4%

Returns & dividend

Return on equity: −33.7%
Return on assets: −19.0%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioNexus Gene Lab Corp. (BGLC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

BioNexus Gene Lab Corp. has a market value of $4.7M and an enterprise value of $1.5M.
Revenue in the twelve months to 30 June 2026: $3.1M. The latest quarter shrank 96.6% year on year.
Net income over the same four quarters: −$2.6M, a −82.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$854K.
Shares outstanding: 2.4M.
Trailing P/E: −1.0×.
BioNexus Gene Lab Corp. employs 19 people — $165K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

BGLC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSpecialty Chemicals

Company	Market cap	TKN rank
BGLCBioNexus Gene Lab Corp.	$4.7M	24
SNESSenesTech, Inc.	$4.6M	29
CNEYCN Energy Group, Inc.	$4.4M	25
YMATJ-Star Holding Co., Ltd.	$8.3M	13
BONBon Natural Life Ltd.	$9.0M	8
LOOPLoop Industries, Inc.	$22.6M	14
FEAM5E Advanced Materials, Inc.	$59.8M	26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioNexus Gene Lab Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BGLC news & analysis

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

GlobeNewsWire · 28 July 2026positive

BioNexus announced continued progress toward commercializing its VitaGuard molecular residual disease platform in Southeast Asia following a working visit to Tongshu Gene facilities in China led by Fidelion's Chief Commercial Officer.

Why it matters — This indicates BioNexus is actively advancing the rollout of its VitaGuard MRD platform in the Southeast Asian market, a key strategic step for the company.

FAQ

Frequently asked questions about BGLC stock

How does Ticker Nerd's model rank BGLC?

As at 12 Sept 2026, BioNexus Gene Lab Corp. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

What is the BGLC stock forecast for 2030?

No analyst covering BioNexus Gene Lab Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BGLC are extrapolating price history, which says nothing about the business.

How has BGLC stock performed over the past year?

BioNexus Gene Lab Corp. returned -62.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioNexus Gene Lab Corp. do?

BioNexus Gene Lab Corp. is a biotechnology and specialty chemicals company based in Kuala Lumpur, Malaysia.

What is the latest news on BGLC?

The most recent item we track (GlobeNewsWire, 28 July 2026): "BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit". BioNexus announced continued progress toward commercializing its VitaGuard molecular residual disease platform in Southeast Asia following a working visit to Tongshu Gene facilities in China led by Fidelion's Chief Commercial Officer.

Company

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. is a biotechnology and specialty chemicals company based in Kuala Lumpur, Malaysia. The company operates through business segments that include industrial chemical trading and genomic screening services. Through its subsidiaries, it supplies chemical raw materials used in industrial, medical, appliance, automotive, mechanical, and electronic manufacturing across Southeast Asia. BioNexus Gene Lab Corp. also develops blood-based diagnostic services that apply functional genomics and RNA analysis to support early disease detection and personalized health management. Its business model combines distribution of specialty materials with laboratory-focused healthcare solutions, positioning the company at the intersection of industrial supply chains and precision diagnostics. This mix gives BioNexus Gene Lab Corp. a role in both regional manufacturing markets and emerging molecular testing services.

CEO Mr. Su-Leng Tan · 19 employees · Malaysia · https://www.bionexusgenelab.com